TITLE

Progression to overweight, obesity and associated factors after antiretroviral therapy initiation among Brazilian persons with HIV/AIDS

AUTHOR(S)
Leite, L. H. Maia; De Mattos Marinho Sampaio, A. B.
PUB. DATE
June 2010
SOURCE
Nutricion Hospitalaria;jul-ago2010, Vol. 25 Issue 4, p635
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Objectives: To assess body weight changes, progression to overweight/obesity and investigate the associated factors among HIV/AIDS patients. Methods: A retrospective study was conducted involving a sample group of 203 adults with HIV/AIDS. Medical records were used to gather demographic, clinical and anthropometric information. The variables were compared by Chi-square tests, Student's t tests and One-way analysis of variance. Results: The majority of the individuals studied were men (72.4%) with an average age of 34.68 ± 8.3 years, and time of HIV infection of 4.12 ± 1.8 years. 63% of the patients gained weight. The greatest weight gain was observed among patients with lower CD4 cell count on admission (8.45 ± 6.6 vs. 5.97 ± 4.97) p = 0.019. 39/203 new cases of overweight/obesity were identified, with a progression rate of 19%. Men were more likely to progress to overweight (p < 0.001) and women to obesity (p < 0.001). A direct and significant relationship was observed between the BMI level on admission and being overweight obese at the end of the study for individuals admitted with normal weight. Conclusions: The results of the study show that in the course of HIV infection overweight/obesity affected men and women admitted with normal weight, although a greater proportion of women progressed to obesity. A higher weight gain contributed in a negative manner to the presence of dyslipidemias in these patients. These data show the importance of monitoring body weight in the course of HIV/AIDS treatment, even in those individuals who present normal body weight.
ACCESSION #
52800746

 

Related Articles

  • Changing Epidemiology of Invasive Fungal Infections: Focus on HIV/AIDS Patients. Antinori, Spinello // Journal of Invasive Fungal Infections;2010, Vol. 3 Issue 4, p105 

    The epidemiology of invasive fungal infections (IFI) in HIV/AIDS patients has changed profoundly since the introduction of highly active antiretroviral therapy (HAART) at the end of 1996. Early initiation of HAART with reversal of severe immunodeficiency is the main factor responsible for the...

  • Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System. Letendre, Scott; Ellis, Ronald J.; Best, Brookie; Bhatt, Archana; Marquie-Beck, Jennifer; LeBlanc, Shannon; Rossi, Steven; Capparelli, Edmund; McCutchan, J. Allen // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Jun2009, Vol. 8 Issue 2, p169 

    Combination antiretroviral therapy (ART) has markedly reduced morbidity and mortality among HIV-infected individuals but not the prevalence of HIV-associated neurocognitive disorders (HAND). Several conditions may be responsible for the high prevalence of cognitive impairment, including...

  • Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Gutierrez, Absalon; Balasubramanyam, Ashok // Endocrine (1355008X);Feb2012, Vol. 41 Issue 1, p1 

    HIV-infected patients on highly active antiretroviral therapy (HAART) have increased prevalence of a number of chronic metabolic disorders of multifactorial but unclear etiology. These include disorders of lipid metabolism with or without lipodystrophy, insulin resistance, and an increased...

  • Does antiretroviral therapy for HIV reduce the risk of developing multiple sclerosis? van der Kop, Mia L. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2015, Vol. 86 Issue 1, p3 

    The article presents a case study that examines the association of HIV and its treatment with antiretroviral therapy (ART) on multiple sclerosis (MS). Topics discussed include use of data of HIV patients between 1999 and 2011 followed up with records of MS, authors of the study showing that the...

  • Prevalence of Pulmonary Tuberculosis Among HIV Positive Patients Attending Antiretroviral Therapy Clinic. Giri, Purushottam A.; Deshpande, Jayant D.; Phalke, Deepak B. // North American Journal of Medical Sciences;Jun2013, Vol. 5 Issue 6, p367 

    Background: Tuberculosis (TB) is the most common serious opportunistic infection in HIV positive patients and is the manifestation of AIDS in more than 50% of cases in developing countries. TB can occur at any time during the course of HIV infection. Aim: To describe the socio-demographic...

  • Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face. Kadouch, J A; van Rozelaar, L; Karim, R B; Hoekzema, R // International Journal of STD & AIDS;Sep2013, Vol. 24 Issue 9, p685 

    Combination antiretroviral therapy (CART) reduces the mortality and morbidity in HIV-infected patients. However, facial lipoatrophy (FLA) is one of the well-known side-effects of this treatment and subsequently imposes major problems for HIV-infected patients. In the last decade, ample...

  • Viral Failure Predicted in Women with Blips.  // Infectious Disease Alert;Dec2008, Vol. 28 Issue 3, p35 

    The article discusses research being done on multivariate predictors of virologic failure (VF). It references a study by A. Geretti et al. presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in October 2008. The researchers examined the risk of VF in...

  • Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera/Eviplera) in the treatment of HIV infection. Bernardini, Claudia; Maggiolo, Franco // Patient Preference & Adherence;2013, Vol. 7, p531 

    The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a oncedaily, single-tablet regimen (STR) containing one nonnucleoside reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved by regulatory agencies (eg, US Food...

  • Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors. Hou-Hsien Chiang; Chien-Ching Hung; Chang-Min Lee; Hsuan-Yu Chen; Mao-Yuan Chen; Wang-Huei Sheng; Szu-Min Hsieh; Hsin-Yun Sun; Chao-Chi Ho; Chong-Jen Yu // Critical Care;2011, Vol. 15 Issue 4, p1 

    Introduction: Although access to highly active antiretroviral therapy (HAART) has prolonged survival and improved life quality, HIV-infected patients with severe immunosuppression or comorbidities may develop complications that require critical care support in intensive care units (ICU). This...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics